Form 4: Ultragenyx Director Sells Over 2,400 Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Ultragenyx Pharmaceutical Inc. Director Corazon D. Sanders sold 2,405 shares of common stock for approximately $90,000 as part of a pre-scheduled Rule 10b5-1 trading plan.
Summary
- Corazon D. Sanders, a Director at Ultragenyx Pharmaceutical Inc. (RARE), reported the sale of 2,405 shares of common stock.
- The transaction occurred on June 20, 2025, at a price of $37.39 per share, resulting in total proceeds of approximately $90,053.95.
- Following this sale, Ms. Sanders beneficially owns 15,344 shares of Ultragenyx common stock.
- The transaction was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.
Sentiment
Score: 6
Explanation: The sale of shares by a director is generally a neutral to slightly negative signal. However, the fact that it was conducted under a Rule 10b5-1 plan mitigates any strong negative sentiment, as it indicates a pre-scheduled, rather than opportunistic, transaction.
Negatives
- Insider selling, even when conducted under a Rule 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.
Risks
- Potential for negative investor sentiment if the sale is misinterpreted as a lack of confidence in the company's future, despite being part of a pre-arranged plan.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. Such transactions are common across various sectors, including pharmaceuticals and biotechnology, for directors and executives managing their personal portfolios.
Stakeholder Impact
- Shareholders: The sale by a director slightly reduces insider ownership, which could be viewed neutrally or with minor concern, though the 10b5-1 plan suggests it's not based on new negative information.
Key Dates
| Date | Description |
|---|---|
| 06/20/2025 | Date of transaction (sale of common stock by Corazon D. Sanders) |
| 06/23/2025 | Date of SEC Form 4 filing |
Keywords
Ultragenyx Pharmaceutical Inc., RARE, Insider Trading, Form 4, Director, Stock Sale, Rule 10b5-1, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.